Biomet Makes Offer to Buy DePuy Business from Johnson and Johnson To Enable Regulatory Clearance for The Purchase of Synthes

Biomet is also in the artificial joint business and corporate offices are located in the UK.  On their websites outside of the US, they have somewhat of a warranty that guarantees their products as they are so durable and back in 2010 they had seen only a dozen claims.  Now this is the type of company that might be able to somehow “fix” some of the stuff going on over at DePuy when it comes to joints replacements.  Depuy has other products as well but the knee and hip failures put them on the map along with Johnson and Johnson being the corporate owner. 
Back in May of 2010 the FDA requested all hip replacement companies to begin studies on failure rates.  Johnson and Johnson bought DePuy in 1998.  DePuy did get FDA approval in June of 2011 for ceramic on metal him implants so who knows what Biomet might be able to do if technologies are combined. 

FDA Requesting Most all Manufacturers of Hip Replacements To Begin Studies On Failure Rates

DePuy Orthopedics Gets FDA Approval For Ceramic-on-Metal Hip Implant Pinnacle CoMplete System–Is This A Potential Replacement for the Other Ones Out There?

Biomet is not without their issues with recently agreeing to pay millions in penalties that they bribed doctors so it appears the may have a better product, but still got in to trouble in other areas.  Upon completion of he Synthes transaction, Synthes and the DePuy Companies of Johnson & Johnson together will comprise the largest business within the Medical Devices and Diagnostics segment of Johnson & Johnson.   BD

Indiana-based Biomet said it has made a binding offer to acquire the trauma business of Johnson & Johnson’s DePuy Orthopeadics subsidiary for approximately $280 million in cash.

The deal is expected to clear the way for New Brunswick-based Johnson & Johnson to receive regulatory approval to complete its acquisition of Synthes. The binding offer allows Depuy to comply with its consultation agreements with various Europeon works councils before it enters a negotiated sale agreement.

DePuy’s trauma business includes a range of products used in reconstructive surgery, including implants, plates and surgical nails as well as specialized technology for treating shoulder, ankle, finger and wrist injuries.

http://www.nj.com/business/index.ssf/2012/04/johnson_johnson_divests_depuy.html